Huang, Alexander C. http://orcid.org/0000-0002-0099-0492
Orlowski, Robert J.
Xu, Xiaowei
Mick, Rosemarie
George, Sangeeth M.
Yan, Patrick K. http://orcid.org/0000-0001-6124-1615
Manne, Sasikanth
Kraya, Adam A.
Wubbenhorst, Bradley
Dorfman, Liza
D’Andrea, Kurt
Wenz, Brandon M.
Liu, Shujing
Chilukuri, Lakshmi
Kozlov, Andrew
Carberry, Mary
Giles, Lydia
Kier, Melanie W.
Quagliarello, Felix
McGettigan, Suzanne
Kreider, Kristin
Annamalai, Lakshmanan
Zhao, Qing
Mogg, Robin
Xu, Wei
Blumenschein, Wendy M.
Yearley, Jennifer H.
Linette, Gerald P.
Amaravadi, Ravi K.
Schuchter, Lynn M.
Herati, Ramin S.
Bengsch, Bertram
Nathanson, Katherine L.
Farwell, Michael D.
Karakousis, Giorgos C.
Wherry, E. John http://orcid.org/0000-0003-0477-1956
Mitchell, Tara C. http://orcid.org/0000-0002-8186-7284
Article History
Received: 9 August 2018
Accepted: 15 January 2019
First Online: 25 February 2019
Competing interests
: Merck provided funding and drugs for the clinical trial. Merck performed immunohistochemistry, immunofluorescence, and NanoString assays, and played a role in the analysis of these data. Merck played no role in the design, data collection, decision to publish, or preparation of the manuscript. R.J.O. was at Penn while engaged in this project, but is now currently employed at Merck. L.A., Q.Z., R.M., W.M.B., and J.H.Y. are currently or were employed at Merck when engaged in this project. E.J.W. is a member of the Parker Institute for Cancer Immunotherapy which supported the UPenn cancer immunotherapy program. E.J.W. has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. E.J.W. has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. E.J.W. is a founder of Arsenal Biosciences. T.C.M. has had advisory roles with Bristol-Myers Squibb, Merck, Incyte, Aduro Biotech, and Regeneron.